Victoza gained FDA approval in 2010, for the treatment of Type 2 diabetes, yet only a short time later, adverse reports began coming in to the FDA. Victoza is manufactured by a Danish company, Novo Nordisk; the company was required to conduct a five-year study to determine the risks of pancreatitis, hypoglycemia, serious allergic reactions, pancreatic cancer and thyroid cancer among Victoza patients. Victoza was also approved with the understanding that it would be a second-line defense drug which means it would only be prescribed when other drug treatment was unsuccessful. 

Victoza, a drug used in the treatment of Type 2 diabetes which received FDA approval in  2010, has suffered serious Victoza safety concerns as more patients are reporting adverse health issues after taking the drug. The advocacy group, Public Citizen, filed a petition with the FDA in April of 2012, requesting that Victoza be removed from the market. The group cited higher-than-normal risks of thyroid cancer, pancreatitis, severe allergic reactions, kidney failure and pancreatic cancer, stating these risks far outweighed the benefits of the drug.

For all those who have been harmed from taking a drug which was not well-tested or simply turned out to be dangerous, their only recourse may be to file a lawsuit against the manufacturer of the drug in order to obtain compensation for their injuries. Byetta is one such drug; research has shown that Byetta may bring potential risks of serious illness among those taking the drug. Byetta was developed to treat Type 2 diabetes, along with diet and exercise by controlling blood sugar in the body when it becomes too high.

Those patients taking the drug Victoza for the treatment of their Type 2 diabetes are likely to have a number of questions regarding the safety of the drug. Whether the drug causes such serious health problems as pancreatic cancer, thyroid cancer, kidney disease and pancreatitis is currently being debated with a number of studies pointing to these dangers. Several studies have placed the risks of a patient taking Victoza and developing pancreatitis at as much as three times that of those taking an older diabetes drug, and the risks of pancreatic cancer is significantly increased as well. Victoza works by mimicking the actions of incretin hormones in the body.

Byetta, a drug approved for the treatment of Type 2 diabetes may carry significant risks for diseases such as thyroid cancer, pancreatitis and pancreatic cancer. Byetta, a synthesized version of a hormone found in the saliva of the Southwestern Gila lizard, is taken by the patient via an injection twice daily prior to breakfast and dinner. The active ingredient in Byetta is exenatide and is in a class of drugs known as incretin mimetcs. Exenatide imitates the actions of incretin which is normally produced by the intestines to suppress the release of glucose from the liver.